Wegovy demonstrated significant and sustained weight loss in two-year study in adults with obesity – Novo Nordisk

Results from the STEP 5 phase IIIb trial, presented by Novo Nordisk at the Obesity Week 2021 interactive congress, showed that adults treated with Wegovy (semaglutide 2.4 mg injection) achieved significant and sustained weight loss over the two-year study period . The STEP 5 trial investigated Wegovy vs. placebo, both used with a reduced calorie meal plan and increased physical […]

Cutting 250 calories daily and exercising may improve heart health in obese older adults

Cutting just 250 calories a day with moderate exercise reaped bigger rewards than exercise alone for older, obese adults. Among older adults with obesity, combining aerobic exercise with a moderate reduction in daily calories resulted in greater improvements in aortic stiffness (a measure of vascular health, which impacts cardiovascular disease), compared to exercise only or to exercise plus a more […]

Testosterone therapy may reduce non-alcoholic fatty liver disease in obese

According to a new study, testosterone therapy may reduce non-alcoholic fatty liver disease in obese men with functional hypogonadism and type-2 diabetes. Testosterone therapy may help obese men with functional hypogonadism and type-2 diabetes reduce the prevalence of non-alcoholic fatty liver disease (NAFLD), according to a study being presented at the 23rd European Congress of Endocrinology (e-ECE 2021), (http://www.ece2021.org). The […]

CHMP recommends expanded approval for Saxenda in obesity – Novo Nordisk

Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351 medicalupdateonline.com is brought to you by International Medical Information. For more details, visit http://www.medicalimi.com Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot […]

Semaglutide reduces excess body fat in people with obesity

In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass, according to an industry-sponsored study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting. “Our findings suggest that semaglutide, through body weight loss and improvement of body composition, has the potential […]